Study objective:To determine whether current therapies are useful in preventing postherpetic neuralgia (PHN) by analysis of study designs and pooled results.
Design:Meta-analysis of all controlled studies investigating PHN prevention in the immunocompetent host. Articles were identified through MEDLINE, Index Medicus and bibliographic reviews of major texts and review articles. Studies meeting eligibility criteria were independently assessed using explicit methodologic criteria for validity and generalizability in clinical trials. Pooled analysis was also performed where appropriate.
Measurements and main results:Twenty-one investigations met eligibility criteria and primarily addressed the use of antiviral agents and corticosteroids. Among studies with strong designs, no evidence of benefit was found for acyclovir or corticosteroids. Pooled results showed no significant effect of acyclovir on the prevention of PHN (odds ratio 0.81, 95% confidence interval 0.56, 1.11). The strongest studies that found potential efficacy in PHN prevention involved adenosine monophosphate and idoxuridine in dimethyl sulfoxide, but problems with clinical application limit the use of these compounds. Outcome definition, compliance assessment, power estimation, and method of randomization were infrequently addressed aspects of design.
Conclusion:Currently there is no proven useful therapy for the prevention of PHN. The benefits of acyclovir and corticosteroids are limited but key questions remain regarding these medications. A clear consensus definition of PHN is needed to improve future investigations.
Sackett DL, Haynes RE, Tugwell P, eds. Clinical epidemiology: a basic science for clinicians. Boston, Little, Brown and Co., 1985;171–97.Google Scholar
DerSimonian R, Charette LJ, McPeek B, Mostellar F. Reporting on methods in clinical trials. N Engl J Med. 1982;306:1332–7.PubMedCrossRefGoogle Scholar
Esmann V, Ipsen J, Peterslund NA, Seyer-Hansen K, Schonheyder H, Juhl H. Therapy of acute herpes zoster with acyclovir in the non-immunocompromised host. Am J Med. 1982;73:320–5.PubMedCrossRefGoogle Scholar
McGill J, MacDonald DR, Fall C, McKendrick GDW, Coppelstone A. Intravenous acyclovir in acute herpes zoster infection. Infection. 1983;6:157–61.CrossRefGoogle Scholar
Juel-Jensen BE, Khan JA, Pasvol G. High dose intravenous acyclovir in the treatment of zoster: a double-blind, placebo controlled trial. J Infect. 1983;6(suppl. 1):31–6.PubMedCrossRefGoogle Scholar
McKendrick MW, Care C, Burke C, Hickmott E, McKendrick GDW. Oral acyclovir in herpes zoster. J Antimicrob Chemother. 1984;15:661–5.CrossRefGoogle Scholar
Wood MJ, Ogan PH, McKendrick MW, Care DC, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988;85:79–83.PubMedGoogle Scholar
Juel-Jensen BE, MacCallum FO, MacKenzie AMR, Pike MC. Treatment of zoster with idoxuridine in dimethyl sulphoxide: results of two double-blind controlled trials. Br Med J. 1970;4:776–80.PubMedGoogle Scholar
Widenhoff KE, Ipsen J, Esmann V, Ingemann-Jensen J, Poulsen JH. Treatment of herpes zoster with idoxuridine ointment, including a multivariate analysis of symptoms and signs. Scand J Infect Dis. 1979;11:1–9.Google Scholar
Wildenhoff KE, Esmann V, Ipsen J. Treatment of trigeminal and thoracic zoster with idoxuridine. Scand J Infect Dis. 1981;13:257–62.PubMedGoogle Scholar
Sklar SH, Blue WT, Alexander EF, Bodian CA. Herpes zoster: the treatment and prevention of neuralgia with adenosine monophosphate. JAMA. 1985;253:1427–30.PubMedCrossRefGoogle Scholar